Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$59.27
-$0.34(-0.44%)
At close: 4:00 PM EST
$59.27
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)718.79K
Market Cap
$2.66B
Enterprise Value$3.64B
Total Cash (Recent Filing)$363.37M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)21.0
Beta0.63
Next Earnings
May 07, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.31
Shares Outstanding46,471,350
10 Day Avg. Volume503,933
30 Day Avg. Volume718,795
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda9.68
Forecast
1Y Price Target
$80.50Price Target Upside35.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)5.31
Revenue Forecast (FY)$1.39B
Bulls Say, Bears Say
Bulls Say
Label ExpansionFDA approval expanded the Vascade MVP XL label to allow use with a wider range of vascular access sheath sizes, increasing the device's applicability in more procedures and supporting potential hospital contract opportunities.
Plasma Growth And Cash FlowPlasma business is delivering strong organic growth and market share gains that are boosting revenue, expanding margins, and supporting improved operating and free cash flow.
Product Portfolio ExpansionAcquisition of Vivasure Medical brings the PerQseal Elite large-bore vascular closure device into the lineup, filling a prior product gap and enabling leverage of existing commercial channels to engage physicians and integrated delivery networks.
Bears Say
Balance Sheet LeverageThe company carries a substantial amount of debt on the balance sheet, creating leverage risk that could constrain strategic flexibility and increase earnings volatility in adverse conditions.
Interventional Technologies WeaknessUnderperformance in Interventional Technologies, including softness in esophageal cooling and supplier-related headwinds in sensor-guided products, has weighed on hospital segment sales and pressured overall results.
Regulatory And Competitive Risk For PerQsealPerQseal is not yet approved for use in the United States, creating a key commercialization hurdle while the large-bore closure market becomes more competitive, which could limit market share and pressure margins.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $2.66B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Feb 05, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.06.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.27.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 46,471,350 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.31 in its last earnings report, beating expectations of $1.25. Following the earnings report the stock price went down -1.41%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.50 (35.82% Upside)
$80.50 (35.82% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.29%
12-Months-Change
Fundamentals
Return on Equity
20.26%
Trailing 12-Months
Asset Growth
-1.60%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported durable organic growth (notably in plasma and blood management technologies), margin expansion, accelerating cash generation, and raised guidance for revenue and free cash flow. These positives outweigh the clear near-term challenges in Interventional Technologies (driven by PFA adoption, OEM dynamics and order timing), vascular closure share loss in select accounts, and the lingering reported revenue impact from prior portfolio transitions. Management outlined funded remediation plans for IVT (MVP XL label expansion and PercuSeal Elite launch) and expects IVT to return to growth in FY2027, supporting a positive outlook.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$80.50
▲(35.82% Upside)
Technical Analysis
Ownership Overview
1.39% Insiders
35.19% Mutual Funds
22.29% Other Institutional Investors
14.83% Public Companies and
Individual Investors